A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment

Targeted Oncology

Volumn 9, Issue 2, 2014, Pages 177-180

  Shablak, Alaaeldin ^a   Conn, Andrew ^a  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cetuximab; EGFR; Interstitial lung disease

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EMOLLIENT AGENT; FLUCLOXACILLIN; FLUOROURACIL; IRINOTECAN; METHYLPREDNISOLONE; OXALIPLATIN; OXYTETRACYCLINE; PARACETAMOL; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACNE; ADULT; ANAMNESIS; ARTICLE; BRONCHOSCOPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DYSPNEA; HUMAN; INTERSTITIAL LUNG DISEASE; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG INFECTION; LUNG LAVAGE; LUNG TOXICITY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; OXYGEN SATURATION; PNEUMONIA; PRIORITY JOURNAL; RECTUM CARCINOMA; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; TISSUE DISTRIBUTION; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; FATALITY; NEOPLASM METASTASIS; PATHOLOGY; SALVAGE THERAPY; SECONDARY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FATAL OUTCOME; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY;

EID: 84902457136     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0295-4     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108 (Pubitemid 40372904)
2. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/ incidence/
3. Kindler HL, Shulman KL (2001) Metastatic colorectal cancer. Curr Treat Options in Oncol 2(6):459-471
4. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50(1):7-33 (Pubitemid 30072093)
5. Wils J, Sahmoud T, Sobrero A, Bleiberg H, Ahmedzai S, Blazeby J, Blijham G, Conroy T, Cunningham D, Curran D, Diaz-Rubio E, Ducreux M, Evans J, Glimelius B, Hutchinson G, Kerr D, Kiebert G, Kohne H, Labianca R, Langendijk R, Nitti D, Nordlinger B, Rougier P, Scheithauer W, Therasse P et al (1998) Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Tumori 84(3): 335-347 (Pubitemid 28313353)
6. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408-1417. doi:10.1056/NEJMoa0805019
7. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, Kohne CH (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Annal Oncol Off J Eur Soc Med Oncol/ESMO 17(3):450-456. doi:10.1093/annonc/mdj084
8. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T, Van Laethem JL, Soulie P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25(33):5225-5232. doi:10.1200/JCO.2007.13.2183 (Pubitemid 350232254)
9. Troiani T, Zappavigna S,Martinelli E,Addeo SR, Stiuso P, Ciardiello F, Caraglia M (2013) Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 13(2):241-255. doi:10.1517/14712598.2012.756469
10. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992-3995. doi:10.1158/0008-5472.CAN-06-0191
11. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96(8):1166-1169. doi:10.1038/sj.bjc.6603685 (Pubitemid 46625066)
12. Erbitux (Cetuximab) Package insert. ECP Inclone Systems Incorporated NYN, Bristol-Myers Squibb Co PN. http://packageinserts.bms.com/pi/pi-erbitux.pdf. Accessed January 2013
13. Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12(5):601-609. doi:10.1634/theoncologist. 12-5-601
14. Danson S, Blackhall F, Hulse P, Ranson M (2005) Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf Int J Med Toxicol Drug Experience 28(2):103-113 (Pubitemid 40321766)
15. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8(4):303-306 (Pubitemid 36929716)
16. Erbitux (cetuximab) Product Information EcP ImClone Systems Incorporated; New York, NY 10014. http://www.erbitux.com. Accessed January 2013
17. Chua W, Peters M, Loneragan R, Clarke S (2009) Cetuximab-associated pulmonary toxicity. Clinical Color Cancer 8(2):118-120. doi:10.3816/CCC.2009.n. 019
18. Ishiguro M, Watanabe T, Yamaguchi K, Satoh T, Ito H, Seriu T, Sakata Y, Sugihara K (2012) A Japanese post-marketing surveillance of cetuximab (Erbitux(R)) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 42(4):287-294. doi:10.1093/jjco/hys005
19. Achermann Y, Frauenfelder T, Obrist S, Zaugg K, Corti N, Gunthard HF (2012) A rare but severe pulmonary side effect of cetuximab in two patients. BMJ Case Rep. doi:10.1136/bcr-03-2012-5973
20. Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, Hoopes CW (2007) Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant off Publ Int Soc Heart Transplant 26(12):1340-1344. doi:10.1016/j.healun.2007.09.019 (Pubitemid 350256993)
21. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N (2004) Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1):93-104. doi:10.1016/j.lungcan.2004.01.010 (Pubitemid 38757837)
22. Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME (2009) Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res CR 28:113. doi:10.1186/1756-9966-28-113
23. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA (2006) Pulmonary toxicity from novel antineoplastic agents. Annal Oncol Off J Eur Soc Med Oncol/ESMO 17(3):372-379. doi:10.1093/annonc/mdj057